NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Some women may be unaware they're living with risks for heart disease, kidney disease and metabolic conditions like diabetes, which drive risk for cardiovascular disease. The interplay among these ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes ... Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company’s industry-leading portfolio ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 – covering burden, and the value of treatment and prevention ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

Millions of women may be unknowingly living with risk factors for heart, kidney and metabolic disease—interconnected ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish ...

The Royal Danish Embassy in Thailand, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. (“Novo Nordisk”), organised ...